Top in endocrinology: Tirzepatide beats semaglutide; menopausal hormone therapy and CV risk
Click Here to Manage Email Alerts
Patients with overweight or obesity assigned tirzepatide lost more weight compared with those assigned semaglutide, according to new results from the SURMOUNT-5 trial announced by Eli Lilly.
Researchers found that among study participants with overweight or obesity and at least one weight-related comorbidity but without diabetes, the group who took tirzepatide (Zepbound, Eli Lilly) had an average weight loss of 20.2% compared with 13.7% for the semaglutide (Wegovy, Novo Nordisk) group.
“We are thrilled that today’s findings showed the superior weight loss of Zepbound, which helped patients achieve 47% more relative weight loss compared to Wegovy,” Leonard C. Glass, MD, FACE, senior vice president of global medical affairs at Lilly Cardiometabolic Health, said in the release. “Zepbound is in a class of its own as the only FDA-approved dual GIP and GLP-1 receptor agonist obesity medication, and it’s changing how millions of people manage this chronic disease.”
It was the top story in endocrinology last week.
In another top story, researchers found that different combinations and administrations of menopausal hormone therapy have varying effects on cardiovascular disease risk.
Read these and more top stories in endocrinology below:
Zepbound bests Wegovy in head-to-head weight-loss trial
Eli Lilly announced top-line results of the SURMOUNT-5 trial in which patients with overweight or obesity assigned tirzepatide lost more weight than those assigned semaglutide. Read more.
CV risks vary based on menopausal hormone therapy combinations, administration methods
Cardiovascular disease risks vary depending on the type of menopausal hormone therapy combinations and administration methods used, according to results of a nationwide trial published in The BMJ. Read more.
Coronary artery disease screening shows no benefit for individuals with diabetes
Coronary CT angiography screening of asymptomatic adults with diabetes for coronary artery disease did not significantly lower mortality or nonfatal myocardial infarction risk, according to longer follow-up of the FACTOR-64 study presented at the American Heart Association Scientific Sessions. Read more.
Pioglitazone added to insulin increases ischemic heart disease risk in type 2 diabetes
Adults with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, findings published in the Journal of Diabetes and Its Complications revealed. Read more.
VIDEO: GLP-1s ‘not the only tool in our armamentarium’ for obesity treatment
In this Healio video exclusive, Katherine H. Saunders, MD, DABOM, discusses important considerations for appropriate prescription of weight-loss medications. Watch here.